{"id":"placebo-for-atogepant","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3991065","moleculeType":"Small molecule","molecularWeight":"603.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (atogepant) through comparison. It contains no active pharmaceutical ingredient and produces no direct therapeutic effect beyond potential placebo response.","oneSentence":"This is a placebo control with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:21.430Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in atogepant clinical trials for migraine prevention"}]},"trialDetails":[{"nctId":"NCT06241313","phase":"PHASE3","title":"Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-03-25","conditions":"Migraine","enrollment":1300},{"nctId":"NCT05711394","phase":"PHASE3","title":"A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-05-01","conditions":"Episodic Migraine","enrollment":450},{"nctId":"NCT06806293","phase":"PHASE3","title":"Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-02-10","conditions":"Menstrual Migraine (MM)","enrollment":430},{"nctId":"NCT06810505","phase":"PHASE3","title":"A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-02-13","conditions":"Chronic Migraine","enrollment":420},{"nctId":"NCT05748483","phase":"PHASE3","title":"Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-10-07","conditions":"Migraine","enrollment":545},{"nctId":"NCT05861427","phase":"PHASE3","title":"Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-07-12","conditions":"Migraine","enrollment":523},{"nctId":"NCT04740827","phase":"PHASE3","title":"Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.","status":"COMPLETED","sponsor":"Allergan","startDate":"2021-03-05","conditions":"Episodic Migraine","enrollment":315},{"nctId":"NCT03855137","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-03-11","conditions":"Chronic Migraine","enrollment":778},{"nctId":"NCT03777059","phase":"PHASE3","title":"12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2018-12-14","conditions":"Episodic Migraine","enrollment":910},{"nctId":"NCT02848326","phase":"PHASE2, PHASE3","title":"Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-09-06","conditions":"Migraine, With or Without Aura","enrollment":834}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Atogepant","genericName":"Placebo for Atogepant","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control with no active pharmacological mechanism. Used for Control arm in atogepant clinical trials for migraine prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}